Is Regeneron Pharmaceuticals Still a Top Growth Stock?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to create a dominant eye-disease franchise, led by Eylea (aflibercept), the best-selling anti-VEGF drug in the market. The biotech has also collaborated with Sanofi to develop cutting-edge therapies for cancer, inflammatory diseases, and lung disorders.
The two companies amended their 2015 immuno-oncology collaboration agreement last year, giving Regeneron worldwide exclusive license rights to Libtayo. However, Sanofi and Regeneron continue to reap the benefits of their blockbuster immunology drug, Dupixent, which generated a staggering $8.68 billion in sales in 2022. With several promising label expansion projects under way, analysts predict that this powerful immunology drug could reach $20 billion in annual sales by 2030.
Image Source: Getty Images.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
Regeneron Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Ein positives Kurspotenzial für Regeneron Pharmaceuticals Inc. ist gegeben, mit einem Kursziel von 1040 € über dem aktuellen Kurs von 1000.5 €.
